During the past decade, University General Hospital of Larissa conducted 120 clinical trials. In the 10-year time frame, 120 clinical trials started and 34 clinical trials were completed, i.e. on average, 28.3% percent of trials that started reached the finish line to date. In the past 5 years, 72 clinical trials started and 26 clinical trials were completed. i.e. 36.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University General Hospital of Larissa" #1 sponsor was "Hellenic Oncology Research Group" with 26 trials, followed by "Hoffmann-La Roche" with 20 trials sponsored, "Larissa University Hospital" with 20 trials sponsored, "University of Thessaly" with 17 trials sponsored and "Eli Lilly and Company" with 17 trials sponsored. Other sponsors include 89 different institutions and companies that sponsored additional 54 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University General Hospital of Larissa" #1 collaborator was "University Hospital of Crete" with 20 trials as a collaborator, "University of Thessaly" with 12 trials as a collaborator, "Larissa University Hospital" with 3 trials as a collaborator, "Allergan" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 28 different institutions and companies that were collaborators in the rest 38 trials.

According to Clinical.Site data, the most researched conditions in "University General Hospital of Larissa" are "Breast Cancer" (17 trials), "Atrial Fibrillation" (5 trials), "Breast Neoplasms" (5 trials), "Cardiac Arrest" (4 trials) and "Idiopathic Pulmonary Fibrosis" (4 trials). Many other conditions were trialed in "University General Hospital of Larissa" in a lesser frequency.

Most popular intervention types in "University General Hospital of Larissa" are "Drug" (134 trials), "Other" (25 trials), "Procedure" (9 trials), "Biological" (6 trials) and "Device" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (35 trials), "Docetaxel" (12 trials), "Bevacizumab" (9 trials), "Paclitaxel" (9 trials) and "Carboplatin" (7 trials). Other intervention names were less common.

The vast majority of trials in "University General Hospital of Larissa" are 161 trials for "All" genders, 19 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are 63 active trials in "University General Hospital of Larissa". 2 are not yet recruiting, 39 are recruiting, 21 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 88 completed trials in University General Hospital of Larissa, undefined suspended trials, and 21 terminated clinical trials to date.

Out of the total trials that were conducted in University General Hospital of Larissa, 9 "Phase 1" clinical trials were conducted, 52 "Phase 2" clinical trials and 73 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 25 trials that are defined as “Not Applicable".

University General Hospital of Larissa has several departments that took part in Clinical trials: "Univeristy Hospital of Larissa; Nephrology" - 8 trials